Jessica A. Hellyer

1.3k total citations
29 papers, 738 citations indexed

About

Jessica A. Hellyer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jessica A. Hellyer has authored 29 papers receiving a total of 738 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Jessica A. Hellyer's work include Lung Cancer Treatments and Mutations (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Myasthenia Gravis and Thymoma (5 papers). Jessica A. Hellyer is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Myasthenia Gravis and Thymoma (5 papers). Jessica A. Hellyer collaborates with scholars based in United States, France and United Kingdom. Jessica A. Hellyer's co-authors include Heather A. Wakelee, Sukhmani K. Padda, Maximilian Diehn, Joel W. Neal, Kavitha Ramchandran, Millie Das, Jacqueline V. Aredo, Henning Stehr, Jonathan W. Riess and Youngtae Jeong and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The American Journal of Cardiology.

In The Last Decade

Jessica A. Hellyer

29 papers receiving 731 citations

Peers

Countries citing papers authored by Jessica A. Hellyer

Since Specialization

Citations

This map shows the geographic impact of Jessica A. Hellyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jessica A. Hellyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jessica A. Hellyer more than expected).

Fields of papers citing papers by Jessica A. Hellyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jessica A. Hellyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jessica A. Hellyer. The network helps show where Jessica A. Hellyer may publish in the future.

Co-authorship network of co-authors of Jessica A. Hellyer

This figure shows the co-authorship network connecting the top 25 collaborators of Jessica A. Hellyer. A scholar is included among the top collaborators of Jessica A. Hellyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jessica A. Hellyer. Jessica A. Hellyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of Exigent Research Network’s partnership with the Tempus AI TIME Program on the screening and matching of patients for clinical trials. 2024 ·Journal of Clinical Oncology ·Ajeet Gajra, (unknown), Sibel Blau, Julio A. Peguero, Mahran Shoukier, (unknown), (unknown), (unknown), (unknown), (unknown), Stephan DiSean Kendall, James Orsini, Sunil Babu, Jessica A. Hellyer, (unknown), (unknown), (unknown), (unknown), (unknown), Matthew M. Cooney	1
2	Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study. 2024 ·Journal of Clinical Oncology ·Jérôme Fayette, Florian Clatot, Irene Braña, Esma Saâda, (unknown), Thibault Mazard, Cesar A. Perez, Josep Tabernero, Christophe Le Tourneau, Antoine Hollebecque, (unknown), Elisa Fontana, Shumei Kato, Assuntina G. Sacco, (unknown), Jan Paul de Boer, Jessica A. Hellyer, (unknown), Andrew K. Joe, Amaury Daste	12
3	Autoimmune Disease in Patients With Advanced Thymic Epithelial Tumors 2022 ·JTO Clinical and Research Reports ·(unknown), Jessica A. Hellyer, Madhu M. Ouseph, Heather A. Wakelee, Sukhmani K. Padda	5
4	Predictive Model to Guide Brain Magnetic Resonance Imaging Surveillance in Patients With Metastatic Lung Cancer: Impact on Real-World Outcomes 2022 ·JCO Precision Oncology ·Julie Wu, Victoria Y. Ding, Sophia J. Luo, Eunji Choi, Jessica A. Hellyer, Nathaniel J. Myall, Solomon Henry, Douglas Wood, Henning Stehr, Hanlee P. Ji, Seema Nagpal, Melanie Hayden Gephart, Heather A. Wakelee, Joel W. Neal, Summer S. Han	4
5	Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer 2021 ·Clinical Lung Cancer ·Jessica A. Hellyer, (unknown), Rebecca M. Gardner, Kristen Cunanan, Sukhmani K. Padda, Millie Das, Kavitha Ramchandran, Joel W. Neal, Heather A. Wakelee	17
6	Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo 2021 ·Cancer Discovery ·Giorgia Foggetti, Chuan Li, Hongchen Cai, Jessica A. Hellyer, (unknown), Deborah Ayeni, Katherine Hastings, Jungmin Choi, Anna Wurtz, Laura Andrejka, Dylan G. Maghini, (unknown), (unknown), Robert Homer, Scott Gettinger, Maximilian Diehn, Heather A. Wakelee, Dmitri A. Petrov, Monte M. Winslow, Katerina Politi	68
7	MO01.01 Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy 2021 ·Journal of Thoracic Oncology ·Jacqueline V. Aredo, Jessica A. Hellyer, Joel W. Neal, Sukhmani K. Padda, Caroline E. McCoach, Jonathan W. Riess, Elwyn C. Cabebe, Billy W. Loo, Maximilian Diehn, Heather A. Wakelee	1
8	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy 2021 ·Journal of Thoracic Oncology ·Jacqueline V. Aredo, Isa Mambetsariev, Jessica A. Hellyer, Arya Amini, Joel W. Neal, Sukhmani K. Padda, Caroline E. McCoach, Jonathan W. Riess, Elwyn C. Cabebe, Jarushka Naidoo, (unknown), Ravi Salgia, Billy W. Loo, Maximilian Diehn, Summer S. Han, Heather A. Wakelee	86
9	Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC 2021 ·Journal of Thoracic Oncology ·Jessica A. Hellyer, Jacqueline V. Aredo, Millie Das, Kavitha Ramchandran, Sukhmani K. Padda, Joel W. Neal, Heather A. Wakelee	43
10	Everolimus in the treatment of metastatic thymic epithelial tumors 2020 ·Lung Cancer ·Jessica A. Hellyer, Madhu M. Ouseph, Sukhmani K. Padda, Heather A. Wakelee	12
11	Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC 2020 ·Journal of Thoracic Oncology ·Jessica A. Hellyer, Sukhmani K. Padda, Maximilian Diehn, Heather A. Wakelee	39
12	Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer 2019 ·Clinical Cancer Research ·Youngtae Jeong, Jessica A. Hellyer, Henning Stehr, Ngoc T. Hoang, Xiaomin Niu, Millie Das, Sukhmani K. Padda, Kavitha Ramchandran, Joel W. Neal, Heather A. Wakelee, Maximilian Diehn	80
13	Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies 2019 ·Lung Cancer ·Jessica A. Hellyer, Matthew A. Gubens, Kristen Cunanan, Sukhmani K. Padda, Matthew Burns, Aaron John Spittler, Jonathan W. Riess, (unknown), Kavitha Ramchandran, Joel W. Neal, Heather A. Wakelee, Patrick J. Loehrer	11
14	MS04.03 Adjuvant PD-(L)1 Checkpoint Inhibitors 2019 ·Journal of Thoracic Oncology ·Jessica A. Hellyer, Heather A. Wakelee	1
15	Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer 2019 ·Lung Cancer ·Jessica A. Hellyer, Henning Stehr, Millie Das, Sukhmani K. Padda, Kavitha Ramchandran, Joel W. Neal, Maximilian Diehn, Heather A. Wakelee	34
16	Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer 2017 ·Breast Cancer Research and Treatment ·Melinda L. Telli, Jessica A. Hellyer, William Audeh, Kristin C. Jensen, Shikha Bose, Kirsten M. Timms, Alexander Gutin, Victor Abkevich, (unknown), Chris Neff, Elisha Hughes, Zaina Sangale, Joshua T. Jones, Anne-Renee Hartman, Pei-Jen Chang, Shaveta Vinayak, Richard Wenstrup, James M. Ford	78
17	Pregnancy Complicated by Gorham–Stout Disease and Refractory Chylothorax 2016 ·American Journal of Perinatology Reports ·(unknown), Mājid Shafiq, (unknown), Maurice L. Druzin, Michael Jeng, Stanley G. Rockson, Robert Lowsky, Jessica A. Hellyer	4
18	Impact of Baseline Stroke Risk and Bleeding Risk on Warfarin International Normalized Ratio Control in Atrial Fibrillation (from the TREAT-AF Study) 2016 ·The American Journal of Cardiology ·Jessica A. Hellyer, Farnaz Azarbal, Claire T. Than, Jun Fan, Susan Schmitt, Felix Yang, Susan M. Frayne, Ciaran S. Phibbs, Celina M. Yong, Paul A. Heidenreich, Mintu P. Turakhia	12
19	Autonomic nerve activity and blood pressure in ambulatory dogs 2013 ·Heart Rhythm ·Jessica A. Hellyer, (unknown), (unknown), Alex Y. Tan, Kathleen A. Lane, Changyu Shen, Jheel Patel, Michael C. Fishbein, Peng‐Sheng Chen	7
20	Are maternal and community risk factors associated with the presence of asthma among children placed in foster care? 2012 ·Children and Youth Services Review ·Jessica A. Hellyer, Edward F. Garrido, Christie L. M. Petrenko, Heather N. Taussig	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact